Upstream Bio (UPB) Change in Accured Expenses (2023 - 2026)

Upstream Bio has reported Change in Accured Expenses for 4 years, with the latest figure at $1.2 million in Q1 2026.

• For the quarter ending Q1 2026, Change in Accured Expenses rose 166.4% year-over-year to $1.2 million; the trailing twelve-month figure through Mar 2026 stood at $7.1 million (up 1201.65% YoY), and the FY2025 full-year result was $4.0 million, up 165.48% from the prior year.
• Change in Accured Expenses for Q1 2026 stood at $1.2 million, down from $2.8 million in the prior quarter.
• The five-year high for Change in Accured Expenses was $3.5 million in Q2 2025, with the low at -$1.9 million in Q1 2025.
• Average Change in Accured Expenses over 4 years is $739400.0, with a median of $510500.0 recorded in 2023.
• Peak annual rise in Change in Accured Expenses reached 822.77% in 2025, while the deepest fall reached 285.71% in 2025.
• Tracing UPB's Change in Accured Expenses over 4 years: stood at $639000.0 in 2023, then soared by 174.65% to $1.8 million in 2024, then soared by 60.74% to $2.8 million in 2025, then slumped by 56.43% to $1.2 million in 2026.
• The last three Change in Accured Expenses figures came in at $1.2 million (Q1 2026), $2.8 million (Q4 2025), and -$481000.0 (Q3 2025), per Business Quant data.

Peer Comparison